Table 3.
Patient Demographics
| Demographics | Patients (N = 458) |
|---|---|
| Age, yrs, mean (± SD) | 73 (± 13.1) |
| Male sex, N (%) | 247 (54) |
| Race | |
| Caucasian, N (%) | 419 (91.5) |
| Black, N (%) | 18 (3.9) |
| Native American, N (%) | 2 (0.4) |
| Other, N (%) | 5 (1.1) |
| Unknown, N (%) | 14 (3.1) |
| Mean length of hospital stay, days (± SD) | 4.9 (± 5.3) |
| Mean BMI, kg/m2 ± SD (median) | 29.9 ± 7.32 (29) |
| Mean weight, kg, mean ± SD (median) | 88.5 ± 26 (85) |
| Weight | |
| <50 kg, N (%) | 12 (2.6) |
| >100 kg, N (%) | 124 (27.1) |
| AST 3 × upper limit of normal, N (%) | 7 (1.5) |
| ALT 3 × upper limit of normal, N (%) | 8 (1.7) |
| Past medical history of liver disease, N (%) | 12 (2.6) |
| Indication for dabigatran | |
| Atrial fibrillation, N (%) | 426 (93) |
| VTE, N (%) | 18 (3.9) |
| Aortic thrombus, N (%) | 3 (0.65) |
| Pulmonary embolism, N (%)a | 6 (1.3) |
| Cerebrovascular accident, N (%) | 1 (0.22) |
| Renal artery infarct, N (%) | 1 (0.22) |
| Femoral-popliteal bypass, N (%) | 1 (0.22) |
| Orthopedic surgery prophylaxis (total knee replacement), N (%) | 1 (0.22) |
| Factor V Leiden, N (%) | 1 (0.22) |
| Outpatient prescribing | |
| Dabigatran home medication, N (%) | 208 (45.4) |
| Warfarin home medication, N (%) | 32 (7) |
| Dabigatran continued at discharge, N (%) | 397 (86.7) |
a
Only 1 patient received 5–10 days of parenteral anticoagulant overlap.
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; SD, standard deviation; VTE, venous thromboembolism.